

***Program of the 2nd International Workshop
on Waldenström's macroglobulinemia***

**September 26-30, 2002
Athens, Greece**

Thursday, September 26, 2002 Astir Palace

3:00 PM Registration Desk Opens
6:00 PM **Welcome Reception and Dinner at Astir Palace**

Dr. Dimopoulos (Greece) Welcome Remarks
Dr. Treon (USA)

Mr. Ben Rude (IWMF) Welcome Remarks
Mrs. Anne Mann (RFW) Welcome Remarks

Dr. Robert Kyle (USA) A Tribute to Dr. Jan Waldenström

Friday, September 27, 2002 Astir Palace

7:00 AM Breakfast

**Session I Genetic basis and pathogenesis of WM
Part I Chair: Dr. Pilarski (Canada)**

8:00 AM Dr. Pilarski (Canada)[#] Defining the malignant clone in WM
8:15 AM Dr. Sahota (UK)[#] Origins of the malignant clone in WM
8:30 AM Dr. Fonseca (USA) Cytogenetics of WM
8:45 AM Dr. McMaster (USA) Family Studies in WM
9:00 AM Dr. Shaughnessy (USA) Gene expression profiles in WM

9:15-9:30 Dr. Pilarski (Canada) Panel Discussion

**Session I Genetic basis and pathogenesis of WM
Part II Chair: Dr. Avet-Loiseau (France)**

9:30 AM Dr. Avet-Loiseau (France) 14q32 translocations discriminate IgM MM from WM
9:45 AM Dr. N. Mitsiades (USA) Proteomic analyses in WM
10:00 AM Dr. Leitch (UK)* Dysregulation of apoptosis in WM does not involve NF- κ B

10:15 AM Dr. Adamia (Canada)* Overexpression and novel splice variants of Hyaluronan synthases in WM

10:30-10:45 Dr. Avet-Loiseau (France) Panel Discussion

10:45-11:00 Session Break Refreshments

Session II IgM Monoclonal gammopathies
Chair: Dr. Kyle (USA)

11:00 AM Dr. Kyle (USA) IgM monoclonal gammopathies

11:15 AM Dr. Morra (Italy) Prognostic factors for transformation in IgM MGUS

11:30 AM Dr. Montoto (Spain)* Malignant transformation in IgM MGUS

11:45-12:00 Dr. Kyle (USA) Panel Discussion

12:00-1:15 Lunch

Session III Defining Waldenström's macroglobulinemia
Chair: Dr. Alexanian (USA)

1:15 PM Dr. Remstein (USA) Clinicopathological overview of WM

1:30 PM Dr. San Miguel (Spain) Immunophenotypic characterization of WM

1:45 PM Dr. Roger Owen (UK) Developing diagnostic criteria in WM

2:00 PM Dr. Pangalis (Greece) Differential diagnosis of WM from other B-cell disorders

2:15 PM Dr. Alexanian (USA) Asymptomatic WM

2:30-2:45 Dr. Alexanian (USA) Panel Discussion

Session IV Report of Consensus Panel One
Co-Chairs: Dr. Dimopoulos (Greece)
Dr. Owen (UK)

2:45-4:15 Dr. Owen (UK) Report of Consensus Panel One on the Clinicopathological definition of WM

Dr. Dimopoulos (Greece) Discussion and Consensus Summary

4:15-4:45 Session Break Refreshments

Session V Prognostic Markers in Waldenström's macroglobulinemia
Chair: Dr. Barlogie (USA)

4:45 PM	Dr. Merlini (Italy)	Prognostic Factors in WM
5:00 PM	Dr. Morel (France)	Prognostic Factors in WM: Description of complications during disease evolution
5:15 PM	Dr. Barlogie (USA)	Prognostic factors and response to Fludarabine: Update from a U.S. Intergroup Trial
5:30 PM	Dr. Bjorkholm (Sweden)	Patterns of clinical presentation and outcome in WM
5:45 PM	Dr. Cesana (Italy)*	Smoldering WM: Factors predicting evolution to symptomatic disease
6:00-6:30	Dr. Barlogie (USA)	Panel Discussion
7:30 PM	Night Tour of Athens and Dinner Reception at Dionysos in Plaka	

Saturday, September 28, 2002 Astir Palace

7:00 AM Breakfast

Session VI Report of Consensus Panel Two
Co-Chairs: Dr. Kyle (USA)
Dr. LeBlond (France)

8:00-9:30	Dr. LeBlond (France)	Report of Consensus Panel Two on Prognostic Markers and Criteria to Treat WM
	Dr. Kyle (USA)	Discussion and Consensus Summary
9:30-9:45	Session Break	

Session VII Therapeutics in WM: Alkylator agents and nucleoside analogues
Chair: Dr. Lister (UK)

9:45 AM	Dr. LeBlond (France)	Fludarabine therapy in WM
10:00 AM	Dr. Weber (USA)	Cladribine therapy in WM
10:15 AM	Dr. Rummel (Germany)*	Combination nucleoside analogue and novel alkylator based therapies for WM
10:30 AM	Dr. Lister (UK)	Defining the use of alkylator agents and nucleoside analogues in WM

10:45-11:15 Dr. Lister (UK) Panel Discussion
11:15-1:00 Lunch

Session VIII Therapeutics in WM: Monoclonal Antibodies
Chair: Dr. Kimby (Sweden)

1:00 PM Dr. Treon (USA) Clinical and laboratory studies on the use of monoclonal antibody therapy in WM
1:15 PM Dr. Kimby (Sweden) Enhancing Rituximab efficacy in WM
1:30 PM Dr. Cesano (USA) CD22 directed serotherapy of WM
1:45 PM Dr. Grewal (USA) CD40 directed serotherapy of WM
2:00 PM Dr. Crowley-Nowick (USA) CD52 directed serotherapy of WM
2:15 PM Dr. Byrd (USA) Novel antibodies for the therapy of WM
2:30 PM Dr. Emmanouilides (USA) Radioimmunotherapy of WM

2:45-3:15 Dr. Kimby (Sweden) Panel Discussion

3:15-3:45 Session Break

Session IX Therapeutics in WM: Thalidomide
Chair: Dr. Coleman (USA)

3:45 PM Dr. Greipp (USA) Bone marrow angiogenesis in WM
4:00 PM Dr. Dimopoulos (Greece) Thalidomide-based therapy of WM
4:15 PM Dr. Coleman (USA) Biaxin, Low-dose Thalidomide, and Dexamethasone (BLT-D) in WM
4:30 PM Dr. Zeldis (USA) Thalidomide analogues and other novel agents for the treatment of plasma cell disorders
4:45-5:00 Dr. Coleman (USA) Panel Discussion

Session X Therapeutics in WM: Transplant Therapy
Chair: Dr. Munshi (USA)

5:00 PM Dr. Munshi (USA) High dose chemotherapy with stem cell transplantation in WM
5:15 PM Dr. Anagnostopoulos (USA) Autologous stem cell transplantation in WM
5:30 PM Dr. Tournilhac (France)* Transplantation in WM: The French Experience
5:45 PM Dr. Giralt (USA) Allogeneic stem cell transplantation in WM
6:00 PM Dr. Maloney (USA) Non-myeloablative allogeneic transplantation for WM

6:15-6:45 Dr. Munshi (USA) Panel Discussion

7:30 PM **Bus Departures for Dinner Reception**

Sunday, September 29, 2002

Astir Palace

7:00 AM Breakfast

Session XI Therapeutics in WM: Novel Therapeutic Strategies

Chair: Dr. Anderson (USA)

8:00 AM Dr. Anderson (USA) Targeting plasma cell dyscrasias in their bone marrow microenvironment

8:15 AM Drs. Stein/Nichols (USA)[#] BCL-2 antisense therapy in WM

8:30 AM Dr. Frankel (USA) BCL-2 antisense therapy of WM: A targeted approach to enhance efficacy

q

8:45 AM Dr. Dhodapkar (USA) Dendritic cell mediated immunotherapy of WM

9:00 AM Dr. C. Mitsiades (USA) Novel biologically based therapies for WM

9:15 AM Dr. Al-Katib (USA) WM-WSU SCID mouse model: Utility in developing new therapeutic strategies in WM

9:30-10:00 Dr. Anderson (USA) Panel Discussion

10:00-10:15 Session Break

Session XII Pathogenesis and therapy of IgM related complications

Chair: Dr. Stone (USA)

10:15 AM Dr. Stone (USA) Monoclonal macroglobulins with antibody activity

10:30 AM Dr. Femand (France) Macroglobulinemia with symptomatic auto-antibody activity: How to treat?

10:45 AM Dr. Pestronk (USA) Antigenic targets of serum IgM in WM and IgM MGUS

11:00 AM Dr. Levine (USA) Treatment of IgM related neuropathies

11:15 AM Dr. Gertz (USA) Amyloidosis with IgM monoclonal gammopathies

11:30-12:00 Dr. Stone (USA) Panel Discussion

12:00-1:15 Lunch

